Evidence map›Paper›PMID 36178457›Full record

ArticleThe Journal of experimental medicine2022

BACH2 restricts NK cell maturation and function, limiting immunity to cancer metastasis.

Charlotte J Imianowski, Sarah K Whiteside, Teresa Lozano, Alexander C Evans, Jayme D Benson, Christina J F Courreges, Firas Sadiyah, Colleen M Lau, Nordin D Zandhuis, Francis M Grant and 10 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Restriction of innate Tγδ17 cell plasticity by an AP-1 regulatory axis.bioRxiv : the preprint server for biology · 2024
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Transcriptional control of ILC identity.Frontiers in immunology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 3 countries.

Charlotte J ImianowskiDepartment of Pathology, University of Cambridge, Cambridge, UK.ORCID 0000-0002-7116-7591
Sarah K WhitesideDepartment of Pathology, University of Cambridge, Cambridge, UK.ORCID 0000-0003-4354-4713
Teresa LozanoImmunology Programme, Babraham Institute, Babraham Research Campus, Cambridge, Cambridgeshire, UK.ORCID 0000-0001-7122-5475
Alexander C EvansDepartment of Pathology, University of Cambridge, Cambridge, UK.ORCID 0000-0002-6363-2684
Jayme D BensonDepartment of Pathology, University of Cambridge, Cambridge, UK.ORCID 0000-0002-8828-0195
Christina J F CourregesDepartment of Pathology, University of Cambridge, Cambridge, UK.ORCID 0000-0003-0203-8486
Firas SadiyahDepartment of Pathology, University of Cambridge, Cambridge, UK.ORCID 0000-0002-6067-3800
Colleen M LauImmunology Program, Memorial Sloan-Kettering Cancer Center, New York, NY.ORCID 0000-0001-7538-094X
Nordin D ZandhuisImmunology Programme, Babraham Institute, Babraham Research Campus, Cambridge, Cambridgeshire, UK.ORCID 0000-0001-6628-3726
Francis M GrantImmunology Programme, Babraham Institute, Babraham Research Campus, Cambridge, Cambridgeshire, UK.ORCID 0000-0001-6885-481X
Martijn J SchuijsCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.ORCID 0000-0001-6433-6417
Panagiota VardakaImmunology Programme, Babraham Institute, Babraham Research Campus, Cambridge, Cambridgeshire, UK.ORCID 0000-0002-1253-243X
Paula KuoDepartment of Pathology, University of Cambridge, Cambridge, UK.ORCID 0000-0002-2476-0018
Elizabeth J SoilleuxDepartment of Pathology, University of Cambridge, Cambridge, UK.ORCID 0000-0002-4032-7249
Jie YangDepartment of Pathology, University of Cambridge, Cambridge, UK.ORCID 0000-0001-9157-0532
Joseph C SunImmunology Program, Memorial Sloan-Kettering Cancer Center, New York, NY.ORCID 0000-0001-8062-9033
Tomohiro KurosakiLaboratory of Lymphocyte Differentiation, World Premier International Immunology Frontier Research Center, Osaka University, Osaka, Japan.ORCID 0000-0002-6352-304X
Klaus OkkenhaugDepartment of Pathology, University of Cambridge, Cambridge, UK.ORCID 0000-0002-9432-4051
Timotheus Y F Halim *Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.ORCID 0000-0001-9773-0023
Rahul Roychoudhuri *Department of Pathology, University of Cambridge, Cambridge, UK.ORCID 0000-0002-5392-1853
Babraham Institute · GBUniversity of Cambridge · GBMemorial Sloan Kettering Cancer Center · USRIKEN Center for Integrative Medical Sciences · JP

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Cancer Research UK 24995Cancer Research UK C52623/A22597Medical Research Council MR/S024468/1Medical Research Council MR/S024468/2NCI NIH HHS P30 CA008748Wellcome Trust 105663/Z/14/ZWellcome Trust 204622/Z/16/Z
6 · The paper itself

Abstract

Natural killer (NK) cells are critical to immune surveillance against infections and cancer. Their role in immune surveillance requires that NK cells are present within tissues in a quiescent state. Mechanisms by which NK cells remain quiescent in tissues are incompletely elucidated. The transcriptional repressor BACH2 plays a critical role within the adaptive immune system, but its function within innate lymphocytes has been unclear. Here, we show that BACH2 acts as an intrinsic negative regulator of NK cell maturation and function. BACH2 is expressed within developing and mature NK cells and promotes the maintenance of immature NK cells by restricting their maturation in the presence of weak stimulatory signals. Loss of BACH2 within NK cells results in accumulation of activated NK cells with unrestrained cytotoxic function within tissues, which mediate augmented immune surveillance to pulmonary cancer metastasis. These findings establish a critical function of BACH2 as a global negative regulator of innate cytotoxic function and tumor immune surveillance by NK cells.

Indexed as

Antineoplastic AgentsNeoplasmsBasic-Leucine Zipper Transcription FactorsHumansImmunity, InnateKiller Cells, NaturalAntineoplastic AgentsBACH2 protein, humanBasic-Leucine Zipper Transcription Factors

Identifiers

PMID36178457
PMCPMC9529614
OpenAlexW4298087996

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.